During the past decade, Chongqing University Cancer Hospital conducted 148 clinical trials. In the 10-year time frame, 148 clinical trials started and 4 clinical trials were completed, i.e. on average, 2.7% percent of trials that started reached the finish line to date. In the past 5 years, 116 clinical trials started and 2 clinical trials were completed. i.e. 1.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chongqing University Cancer Hospital" #1 sponsor was "Chongqing University Cancer Hospital" with 16 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 15 trials sponsored, "Janssen Research & Development, LLC" with 13 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored and "BeiGene" with 8 trials sponsored. Other sponsors include 90 different institutions and companies that sponsored additional 66 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chongqing University Cancer Hospital" #1 collaborator was "Eli Lilly and Company" with 5 trials as a collaborator, "Chongqing University Cancer Hospital" with 4 trials as a collaborator, "Eisai Inc." with 4 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator and "Hebei Medical University Fourth Hospital" with 3 trials as a collaborator. Other collaborators include 132 different institutions and companies that were collaborators in the rest 114 trials.

According to Clinical.Site data, the most researched conditions in "Chongqing University Cancer Hospital" are "Advanced Solid Tumor" (7 trials), "Colorectal Cancer" (7 trials), "Ovarian Cancer" (7 trials), "Breast Cancer" (6 trials) and "Carcinoma, Non-Small-Cell Lung" (6 trials). Many other conditions were trialed in "Chongqing University Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Chongqing University Cancer Hospital" are "Drug" (134 trials), "Biological" (15 trials), "Radiation" (14 trials), "Other" (7 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Anlotinib" (10 trials), "Carboplatin" (10 trials), "Paclitaxel" (8 trials) and "Atezolizumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Chongqing University Cancer Hospital" are 108 trials for "All" genders, 33 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are NaN active trials in "Chongqing University Cancer Hospital". 6 are not yet recruiting, 89 are recruiting, 31 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Chongqing University Cancer Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Chongqing University Cancer Hospital, 35 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 69 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 6 trials that are defined as “Not Applicable".